- Open Access
Pituitary gland metastasis from rectal cancer: report of a case and literature review
© Ratti et al.; licensee Springer. 2013
Received: 24 June 2013
Accepted: 9 September 2013
Published: 16 September 2013
Pituitary metastases are unusual complications of malignancies. In about only 2% of patients they origin from colorectal cancer (CRC), with breast and lung as the most common primary tumors. Nevertheless, some authors reported a recent increase of the incidence of metastases in infrequent sites, such as brain or bone, arising from gastrointestinal cancers, probably due to the expanded treatment options and the resulting improved survival. Here, we report the case of a 54-year old woman diagnosed with lung metastases from rectal cancer, who, after several cycles of radio- and chemotherapy, presented symptoms and signs of pituitary disfunction (i.e. diabetes insipidus, hypothyroidism and diplopy). The diagnosis of pituitary metastasis from rectal cancer was histologically confirmed after surgery.
Metastases to the pituitary gland are rare complications of advanced cancer. Data from a large number of autopsies show that pituitary metastases are present in 1–3.6% of patients with malignancies (McCormick et al. 1989). Breast cancer is the most common tumor metastasizing to the pituitary gland, followed by lung, prostate, renal cell and gastrointestinal cancers; lymphoma, leukemia, thyroid carcinoma, and plasmocytoma have also been described (Fassett and Couldwell 2004). Brain metastases from CRC are very uncommon; in a recent analysis a cumulative incidence of 1.2% was reported. In particular, CRC is a rare cause of metastases to the pituitary gland (Schouten et al. 2002). In a series of 380 cases it was the primary tumor in only 2.4% of such cases (9 patients) (Komninos et al. 2004). Before the advent of modern systemic therapies most CRC patients lived for only few months. Late onset metastases in brain or central nervous system rarely developed and patients died before such metastases could occur. Recent therapies allow longer disease-free intervals and better overall survival; this probably explains the current increase in the incidence of metastases from colorectal cancers in uncommon sites, such as brain and/or bone (Go et al. 2011). Here we report an unusual case of a young-adult woman, who developed pituitary metastases from rectal cancer 4 years after the resection of the primary tumor and following prior neo- and adjuvant treatments.
A 54-year old caucasian woman was admitted to the radiotherapy division of our hospital in September 2007, with new diagnosis of adenocarcinoma of the rectum (clinical stage T3, N2, M1 [lung]). The patient, after neoadjuvant radio-chemotherapy (50 Gy totally delivered to the posterior pelvis from September 27th to November 16th associated with Oxaliplatin 75 mg/mq weekly + 5FU 225 mg/mq as a continuous intravenous infusion from September 27th to October 5th, early interrupted after 2 weeks for severe diarrhea and fever), underwent an abdomino-perineal resection of the rectum in January 2008, followed by adjuvant chemotherapy with FOLFOX4 scheme (12 cycles, from February 27th to September 3rd). A CT (computed tomography) scan of her chest revealed a size reduction of the two pulmonary lesions in September 2008.
Subsequent controls (TC and PET scans) showed pulmonary progression of disease and tumor markers increase (i.e. CEA), without any evidence of abdominal relapse in July 2009. The patient agreed to start a new line of chemotherapy in April 2010 only, after a new CT scan carried out in March 2010 showed further increase in size of the pulmonary lesions. Irinotecan 200 mg/m2 and Bevacizumab 7.5 mg/Kg every 3 weeks were administered from April 9th to June 7th (Irinotecan early stopped for gastrointestinal toxicity and patient’s refusal) followed by Bevacizumab alone at a dose of 5 mg/Kg bi-weekly for ten cycles from July until December, with instrumental evidence of stable disease until January 2011, when a CT of her chest and a PET scan revealed a new progression of disease in this site. For this reason, she started a new treatment with Raltitrexed 3 mg/mq q3w in January 2011, early interrupted after 1 cycle for severe bone marrow toxicity.
The patient decided to refuse any further treatment until April 2011, when she was admitted to the Oncology division of our hospital asking for second medical opinion and, after an instrumental restaging, she was enrolled in a clinical trial in May 2011. Because of her wild-type k-ras mutational status, she received Cetuximab 361 mg weekly, for 8 cycles until July 2011, when a restaging CT scan showed the appearance of a new pulmonary lesion. Therefore, patient was offered a new chemotherapy with XELOX scheme (Oxaliplatin 141 mg, day 1, Capecitabine 2500 mg day 2–15 q3w) in August 2011, suspended after the 3rd cycle for moderate neurotoxicity and severe diarrhea. The patient underwent an instrumental re-evaluation with thoraco-abdominal CT scan in October 2011, which evidenced dimensional increase of pulmonary lesions.
Taking into consideration the previous chemotherapy toxicities and the patient’s reluctance to receiving new potentially toxic agents, we offered a palliative treatment with cyclophosphamide and methotrexate at low continuative doses, which patient started in November 2011. The following CT scan revealed stable disease in February 2012, but the patient decided to interrupt treatment for severe asthenia and mucositis, until April 2012, when, we decided to administer Mitomycin C at the dose of 6 mg/m2 every 4 weeks, after the evidence of further increase in size of the pulmonary lesions.
The patient, after the third cycle of therapy, complained poliuria and polidipsia, but there was no evidence of plasmatic and urinary osmolites alteration. For this reason, we planned a restaging CT, including brain imaging.
Despite the improvement of neurological symptoms after surgery, the patient died of respiratory complications as a result of the lung disease involvement 8 days later, in August 2012.
The pituitary gland is an uncommon site for metastases, in particular from CRC. Breast and lung cancers are the most common diseases spreading to this site (Morita et al. 1998). Teears and Silverman analysed 88 patients with pituitary metastases and noticed that breast and lung were the most frequent sites of the primary tumor (40% and 33%, respectively), whereas 2% of patients only presented CRC as primary site of disease (Teears and Silverman 1975). In the absence of specific series in the literature, the incidence of rectal cancer metastasizing to the pituitary is certainly even lower.
The widest review of literature about pituitary metastases including 380 patients, mentions 9 cases only of primary localization in colorectal site (Komninos et al. 2004). These data confirm the rarity of our report.
Recent studies reveal that the majority of pituitary metastases occur in the posterior lobe. The same work by Teears and coll., reported that 57% of the lesions are localized to the posterior pituitary alone, 13% to the anterior pituitary alone, 12% to both lobes and the remaining to the capsule or stalk (Teears and Silverman 1975).
The majority of pituitary metastases are clinically silent. When the patient is symptomatic, the most common clinical presentation seems to be diabetes insipidus (DI) (45.2%), reflecting a predominance of metastases to the posterior lobe (Sioutos et al. 1996). Other reported symptoms are ophtalmoplegia, headache, visual field defects and anterior pituitary disfunction (Nelson et al. 1987). Additionally, DI is more common in patients with pituitary metastases than in those with adenomas (Morita et al. 1998). In a series of 190 cases of symptomatic pituitary metastasis, DI was reported in 45.2% of patients, optic nerve impairment in 27.9% and anterior pituitary insufficiency in 23.6% (Komninos et al. 2004). Twenty-one percent of patients developed other cranial nerves defects such as 3rd, 4th, and 6th palsy.
In about 25% of the cases the diagnosis is made after laboratory evidence of anterior pituitary failure (Freda and Post 1999).
Radiological evaluation doesn’t really help in distinguishing adenoma from metatasis. High resolution CT and MRI are the most sensitive exams. CT usually shows a hyperdense or isodense mass, enhancing homogeneously or non-homogeneously (if cystic degeneration, hemorrhage, or necrosis co-exist) in contrast images. MRI may demonstrate an isointense or hypointense mass on T1 weighted images, with a usually high-intensity signal on T2 weighted images, homogeneously enhancing post-gadolinium, as well as absence of high-signal intensity from the posterior lobe on T1. Neither of the imaging findings is highly specific and allows to make a correct diagnosis (Schubiger and Haller 1992). The definitive diagnosis of metastatic involvement is always based on histological evaluation, allowing to distinguish from pituitary primary lesions (Go et al. 2011).
Benign lesions more often are functioning masses, frequently producing ACTH and prolactin; on the other hand, metastases might cause disfunction of the pituitary gland and compression of the near anatomic structures (Max et al. 1981).
Treatment, mostly palliative, depends on the symptoms. Surgical exploration and decompression, alone or combined with radiation, is often necessary when suprasellar extension causes progressive deterioration in vision and/or pain (Branch and Laws 1987). In our case, tumor debulking allowed to improve the local symptoms, especially headache and visual field defects such as diplopia and hemianopsia.
Generally, the surgical approach, the completeness of the resection, and an aggressive treatment (surgery plus local radiation) are associated with better symptom relief but do not affect survival rates; in fact, prognosis of patients with MPs is usually poor, with a life expectancy of few months after diagnosis (Komninos et al. 2004).
The peculiarity of the case described above is not only represented by the unusual site of metastasis from rectal cancer, but also by the long history of treatments received by our patient.
Recent studies show that the expanded treatment options and the consequent improved survival for patients with metastatic CRC are associated with an increased incidence of metastases at uncommon sites (Sundermeyer et al. 2005). A comprehensive review on the incidence, prevalence, epidemiology, risk factors, management, and prognosis of brain metastases arising from esophageal, gastric, gallbladder, pancreatic, small bowel, and colorectal cancer reported that brain metastases are found in 1% of colorectal cancer, 1.2% of esophageal cancer, 0.62% of gastric cancer, and 0.33% of pancreatic cancer cases. Survival in patients with brain metastases from gastrointestinal tumors was found to be inferior compared with breast, lung or kidney. Authors concluded that, although early treatment has been linked to prolonged survival and improved quality of life, brain metastases represent a late manifestation of gastrointestinal cancers and remain an ominous sign (Go et al. 2011).
Sundermeyer and colleagues evaluated patients with metastatic CRC from 1993 to 2002 at the Fox Chase Cancer Center, collecting date of diagnosis/metastasis, primary tumor site, therapeutic agents received, survival, and site(s) of metastases. The data demonstrate that the incidence of bone and brain metastases in patients with CRC is more common than previously reported and is associated with the administration of multiple systemic treatments (Sundermeyer et al. 2005).
In conclusion, here we presented the case of a patient affected by metastatic rectal cancer, with a large sellar mass and a long history of oncological treatments.
The rarity of involvement of the pituitary gland from rectal cancer made diagnosis challenging and the histological evaluation helped to confirm the intestinal origin of the lesion. This metastatic event is very uncommon making almost impossible to perform prospective clinical trials specifically designed to compare different treatment approaches. Thus, only a greater awareness of the problem along with a more accurate and timely diagnosis, will lead to choose the best therapies suitable to the specific patient and in turn improve overall prognosis.
Although infrequently, metastatic involvement of the pituitary gland from colorectal cancer can be found and it might become increasingly common in the next future as a result of the expanded treatment options and the consequent improved patients’ survival.
- Branch CL Jr, Laws ER Jr: Metastatic tumors of the sella turcica masquerading as primary pituitary tumors. J Clin Endocrinol Metab 1987, 65: 469-474. 10.1210/jcem-65-3-469View ArticleGoogle Scholar
- Fassett DR, Couldwell WT: Metastases to the pituitary gland. Neurosurg Focus 2004, 16: E8. 10.3171/foc.2004.16.2.1View ArticleGoogle Scholar
- Freda PU, Post KD: Differential diagnosis of sellar masses. Endocrinol Metab Clin North Am 1999, 28: 81-117. vi 10.1016/S0889-8529(05)70058-XView ArticleGoogle Scholar
- Go PH, Klaassen Z, Meadows MC, Chamberlain RS: Gastrointestinal cancer and brain metastasis: a rare and ominous sign. Cancer 2011, 117: 3630-3640. 10.1002/cncr.25940View ArticleGoogle Scholar
- Komninos J, Vlassopoulou V, Protopapa D, et al.: Tumors metastatic to the pituitary gland: case report and literature review. J Clin Endocrinol Metab 2004, 89: 574-580. 10.1210/jc.2003-030395View ArticleGoogle Scholar
- Max MB, Deck MD, Rottenberg DA: Pituitary metastasis: incidence in cancer patients and clinical differentiation from pituitary adenoma. Neurology 1981, 31: 998-1002. 10.1212/WNL.31.8.998View ArticleGoogle Scholar
- McCormick PC, Post KD, Kandji AD, Hays AP: Metastatic carcinoma to the pituitary gland. Br J Neurosurg 1989, 3: 71-79. 10.3109/02688698909001028View ArticleGoogle Scholar
- Morita A, Meyer FB, Laws ER Jr: Symptomatic pituitary metastases. J Neurosurg 1998, 89: 69-73. 10.3171/jns.1998.89.1.0069View ArticleGoogle Scholar
- Nelson PB, Robinson AG, Martinez AJ: Metastatic tumor of the pituitary gland. Neurosurgery 1987, 21: 941-944. 10.1227/00006123-198712000-00030View ArticleGoogle Scholar
- Schouten LJ, Rutten J, Huveneers HA, Twijnstra A: Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 2002, 94: 2698-2705. 10.1002/cncr.10541View ArticleGoogle Scholar
- Schubiger O, Haller D: Metastases to the pituitary-hypothalamic axis. An MR study of 7 symptomatic patients. Neuroradiology 1992, 34: 131-134. 10.1007/BF00588159View ArticleGoogle Scholar
- Sioutos P, Yen V, Arbit E: Pituitary gland metastases. Ann Surg Oncol 1996, 3: 94-99. 10.1007/BF02409058View ArticleGoogle Scholar
- Sundermeyer ML, Meropol NJ, Rogatko A, et al.: Changing patterns of bone and brain metastases in patients with colorectal cancer. Clin Colorectal Cancer 2005, 5: 108-113. 10.3816/CCC.2005.n.022View ArticleGoogle Scholar
- Teears RJ, Silverman EM: Clinicopathologic review of 88 cases of carcinoma metastatic to the pituitary gland. Cancer 1975, 36: 216-220. 10.1002/1097-0142(197507)36:1<216::AID-CNCR2820360123>3.0.CO;2-EView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.